(347) An Ultra-long-acting Atovaquone Prodrug Formulation for Malaria Chemoprophylaxis

Introduction: Despite recent advancements, malaria remains a life-threatening disease to public health. While existing malaria chemoprophylaxis effectively prevents infection, frequent drug dosing and resistance profiles are treatment concerns. Vaccine development is challenging and limited by the parasite's unique immune evasion mechanisms. Thus, there is a need to develop long-acting (LA) formulations for malaria prevention. Atovaquone (ATQ) is an antimalarial drug used for prevention and its inherent molecular properties make it a promising candidate for LA malaria chemoprophylaxis therapy [1].